Connect Biopharma Reports Q3 2025 Results and Advances Rademikibart Clinical Programs
I'm PortAI, I can summarize articles.
Connect Biopharma Holdings Ltd. reported its Q3 2025 financial results, highlighting ongoing recruitment for Phase 2 Seabreeze STAT studies on rademikibart for asthma and COPD, with topline data expected in H1 2026. In China, Simcere submitted a New Drug Application for rademikibart for atopic dermatitis, accepted by the National Medical Products Administration. The company also terminated its American Depositary Receipt program and listed its shares on Nasdaq under "CNTB". As of September 30, 2025, it had $54.8 million in cash and equivalents, sufficient to fund operations into 2027.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments